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The application of functional genomics to
the analysis of breast cancer samples
holds great promise in producing a sub-
stantial advance in breast cancer prog-
nostication. In a recent issue of Nature,
van’t Veer et al. describe their ability to
determine with substantial accuracy
whether a young node-negative patient
will or will not show progressive disease
within five years time (van ‘t Veer et al.,
2002).
This work highlights a painful dispar-
ity in current clinical practice: oncologists
are able to detect tumors of ever smaller
size (current avg.: 1.5 cm diameter) in
the breast, but their ability to exploit the
diagnostic parameters associated with
these relatively small tumors in order to
predict eventual outcome has lagged far
behind.
The oncologic territory has changed
dramatically over the past two decades.
With improving public awareness and
detection techniques, as many as
60%–70% of breast cancer patients cur-
rently present clinically at an early stage
while still being node-negative. That is,
the axillary lymph nodes, which drain
much of the mammary gland, are found
to be free of detectable cancer cells
through light microscopy.
Since the 10-year recurrence rate in
node-positive patients is approximately
70%, the standard practice is to adminis-
ter systemic adjuvant therapy to all
patients in this group. This therapy
involves anti-estrogen treatment (in the
case of estrogen receptor-positive
tumors), Herceptin (in the case of
HER2/neu-positive tumors), and often
cytotoxic drugs.
The treatment decision for node-
negative patients, however, is not as
straightforward. Approximately 70%–
80% of the node-negative group will sur-
vive breast cancer without additional
treatment beyond surgical resection of
the initially detected growth. Hence,
many argue that adjuvant systemic ther-
apy, which can have significant toxicities,
should not be undertaken routinely, since
one risks harming many for the benefit of
a few (Harris et al., 2000; Bland et al.,
1998).
The dramatic shift in the clinical sta-
tus of women at the time of initial presen-
tation in the clinic now creates a sub-
stantial and still-to-be-solved problem,
because many of the standard patholog-
ic prognostic factors currently used were
developed in an earlier era when a
majority of the patients presented with
larger (>2 cm diameter) tumors and were
node-positive.
Among the many studies that have
examined prognostic factors for breast
cancer, only a few have specifically
focused on node-negative patients (Mirza
et al., 2002). Moreover, standard prog-
nostic factors such as tumor size, histo-
logical type, grade of differentiation, and
hormone receptor status were found to
have limited value in predicting which
node-negative patients would relapse.
As a result, physicians have very few
tools available for determining which
node-negative patients should receive
adjuvant therapy.
The landscape has also changed in
yet another respect. Some of the tradi-
tional markers (e.g., estrogen receptor,
ER) have been useful not only to predict
outcome but also to inform therapy, since
anti-ER agents such as tamoxifen have
been available and found useful for
improving short-term survival. Now, with
the advent of novel therapies (e.g.,
Herceptin), other markers, such as
Her2/neu expression, gain in importance
because of their role in conferring
responsiveness to these newly devel-
oped agents.
This complex picture reveals the dis-
ease of breast cancer to be a rapidly
moving target, where the perceived rele-
vance of widely used diagnostic and
prognostic parameters may change dra-
matically over a period of several years.
The mysteries of breast cancer
epidemiology
The number of diagnosed breast can-
cers in the Western world has increased
substantially over the past half century.
For example, in 1990, an estimated
150,000 new cases were reported in the
United States while six years later, the
number had increased to 185,000.
During the same time period, estimated
deaths due to breast cancer remained
constant (44,000) (Harris et al., 2000).
However, there is some hope on the hori-
zon: over the past several years, age-
adjusted mortality of breast cancer has
actually declined slightly (1.7% per
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The clinical treatment of primary breast cancers has been greatly complicated by the inability to accurately predict which
tumors will eventually become invasive and metastatic and which will remain localized and indolent. Lacking the ability to
discriminate between these two classes of breast cancer patients, oncologists often apply aggressive adjuvant therapy to
women in both groups. However, the use of functional genomics analysis has now made it possible to assemble a set of
gene markers, the expression of which enables one to predict, with reasonably high accuracy, whether or not the patient
will relapse or remain tumor-free five years after initial diagnosis and treatment.
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year). The simplest interpretation of
these statistics is that breast cancer is
reaching epidemic proportions, but that
advances in modern medicine have
resulted in an increasing ability to cure
disease. Accordingly, these two counter-
vailing trends cancel each other almost
precisely, leaving the mortality rate
essentially unchanged for the past two
generations.
There is, however, a far different
interpretation of these facts, and it sheds
less flattering light on the practice of
medicine. Some would argue that the
real incidence of breast cancer has
changed only slightly over the past half
century, and that the increased number
of cases really represents a diagnostic
bias. Thus, currently available diagnostic
techniques may be detecting cancers in
women that previously would have elud-
ed detection and would have remained
indolent for the lifetime of the woman,
never emerging to the level of clinical vis-
ibility.
This perspective, in its extreme and
most fatalistic form, assigns breast can-
cers to two categories—those that will
remain non-life-threatening no matter
how they are treated, and those that will
progress, sooner or later, to a lethal out-
come, once again no matter how they
are treated. If this interpretation were
sustained, then cynics might opine that a
substantial proportion of breast cancer
survivors have survived a form of the dis-
ease that in earlier days would have
remained undetected and non-threaten-
ing during the lifetimes of these women.
(A similar argument can also be made for
prostate cancer.)
The real truth probably lies some-
where in between. For example, an ever-
increasing average human life span
might allow slowly growing, indolent
tumors to progress to a clinically signifi-
cant size and state of malignancy.
Moreover, it is likely that there has been
a real and significant increase in breast
cancer incidence, and this increase
remains even after the effects of diag-
nostic bias have been factored in. The
most likely cause of this increase is due
to the hormonal environment of
Western women, which has changed
profoundly over the past century. The
point is made most starkly by referring
to the fact that an 18- or 19-year-old
woman in modern America has gone
through as many menses as her great-
grandmother experienced in a lifetime.
This astounding conclusion flows direct-
ly from the increasingly early age of
menarche, from delayed child-bearing
(thereby forgoing the effects that both
pregnancy and lactation have on sup-
pressing menses), and from a
menopause that is delayed by years
compared with historical averages.
These factors, together with women
missing the protective effects that early
and repeated childbearing exert in
reducing breast cancer risk, should per-
suade even the most hardened cynics
that the real incidence of breast cancer
has indeed grown.
The oncologist’s dilemma
The fact that the majority of breast can-
cers diagnosed these days are unlikely
to lead to fatal outcomes, even without
aggressive intervention, has been of little
consolation to oncologists, who have
been unable to determine with certainty
which tumors will remain indolent and
which, of an identical histology, will
progress sooner or later to a highly
malignant, life-threatening state. Because
diagnostic bias has been increasing the
numbers of breast cancers detected
each year, the oncologist’s dilemma
worsens incrementally, since the propor-
tion of diagnosed tumors that truly justify
aggressive intervention decreases year
after year. Being unable to distinguish
truly worrisome tumors from those that
will remain indolent, oncologists must
treat all lesions equally aggressively.
Hence, the number of breast cancer
patients exposed unnecessarily to ag-
gressive surgery and systemic adjuvant
therapy (chemotherapy and axillary radia-
tion) grows with each passing year.
Hope for successfully dealing with
this dilemma has come from an increas-
ingly diverse array of breast cancer
markers. Ideally, the best of these mark-
ers should be proteins that play impor-
tant causative roles in the tumor cell pro-
liferation and thus cancer progression.
The proteins commonly used in breast
cancer prognostication include Her-2/
Neu, p53, estrogen and progesterone
receptors, and cell proliferation markers
such as Ki-67 and cyclin D1. Historically,
each of these markers emerged from
detailed molecular and biochemical
analyses of breast cancer cell lines and
tumor samples.
Even when these markers are used
together with tumor histopathology to
determine the prognosis of a node-nega-
tive patient, the result is probabilistic
and, as before, the eventual clinical
course far from being a certainty. It
remains unclear whether this ensemble
of markers is intrinsically limited in its
predictive powers, or whether the proper
studies using all these diagnostic para-
meters together on a large patient popu-
lation have yet to be done.
Enter functional genomics
Motivated by the shortcomings of cur-
rent prognostic markers, van’t Veer et
al. screened the mRNA expression pat-
terns of a set of 25,000 genes in tumor
samples from node-negative breast
cancer patients using an oligonucleotide
microarray.Tumor-to-tumor comparisons
revealed that 5000 genes varied in
expression level by more than 2-fold.
The great majority of these genes were
found to have little value in predicting the
known five-year survivals and recur-
rence rates of 78 node-negative patients,
leaving a subset of 231 genes as poten-
tially useful prognostic markers. A mini-
mum set of 70 genes out of the 231,
when analyzed with the proper algo-
rithm, enabled these researchers to pre-
dict with 83% accuracy (i.e., 65/78
tumors) which of the node-negative
patients registered in their data set
would develop distant metastasis during
a five year follow-up period and which
would remain disease-free over this
interval.
Provocatively, none of the clinically
well-established prognostic marker pro-
teins (i.e., members of the short list cited
above) was encoded by a gene in the
subset of 70 marker genes found to have
prognostic utility in this study. This dis-
crepancy could be explained by the fact
that for many genes, there is little corre-
lation between the abundance of its
mRNA transcript with steady-state levels
of encoded protein. Alternatively, the tra-
ditionally used markers may simply have
far less predictive value than the 70
uncovered through this functional
genomics strategy.
A logical weakness in retrospective
studies like this one derives from the fact
that a data set is used to generate a
prognostic strategy, and the utility of the
resulting strategy is then measured by
examining its predictive powers on the
same data set. However, when this func-
tional genomics strategy was tested on a
group of 19 patients who were not mem-
bers of the original cohort, it worked well,
yielding correct predictions in 17 of 19
patients examined. It remains to be seen
whether application of this strategy to a
large cohort of patients studied retro-
spectively, or to a large cohort studied
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prospectively, will reveal predictive pow-
ers that are equally impressive.
Moreover, 10- and 15-year outcomes will
eventually prove to be more relevant,
given the frequently delayed relapses of
breast cancers after this long period of
apparently tumor-free life.
Hope and problems for the future
Will we eventually be able to improve
upon what van’t Veer and colleagues
accomplished in this study? When start-
ing with a cohort of 25,000 genes, as
was done in this paper, it was only possi-
ble to predict the actual outcome accu-
rately in 83% of the patients. Does this
represent an upper limit of success or
could one achieve almost 100% accu-
rate predictions with even more genes in
the starting cohort (there being 6000–
10,000 that were absent from their
array)? An obvious source of improve-
ment might come from dissection of the
carcinoma cells from the stromal cells
with which they are comingled in virtually
all breast carcinomas.Many of the genes
analyzed here are clearly expressed in
one or the other cell type, and the con-
founding effects of stromal gene expres-
sion, contributed by larger or smaller stro-
mal cell populations in different tumors,
are hard to gauge in the absence of such
dissection.
An absolute upper limit to predictive
power might well be due to a subset of
tumors that do not actually express the
predictive information in the primary
tumor sample. Problems may also arise
from heterogeneity of tissue populations
in primary tumor populations; thus, the
sampled area may not represent the
most aggressive portion of the tumor.
Moreover, patient’s exposure to unpre-
dictable environmental factors (radiation,
hormones, etc.) subsequent to tumor
sampling may modify the behavior of the
occult residual disease, both at local and
distant sites.
Even with larger tumor samples and
more powerful expression array analy-
ses, a weighty problem may continue to
dog those intent on generating more
accurate breast cancer prognoses. Use
of all these diagnostic assays, involving
histopathology, ELISA assays, or gene
expression arrays or combinations of two
or three approaches, assume implicitly
that individual breast cancers follow a
small number of alternative genetic
paths during the course of multi-step
tumor progression. These paths, defined
by the sequences of genetic and epige-
netic alterations acquired by tumor cells
during the development of malignancy,
would seem to preordain the ultimate
behavior of the end products of tumor
progression.
The unsettling prospect is that breast
cancer pathogenesis, and by extension
the pathogenesis of many other human
tumor types, is a far more random, disor-
dered process, and that there are
dozens if not hundreds of distinct routes
taken by human breast cancers en route
to full-fledged malignancy. If this were
the case, then the predictive powers of
diagnostic assays will forever be limited
by the involvement of small but signifi-
cant numbers of tumors that take their
own, unique paths, each following the
beat of a quite different drummer.
Some of the initial functional geno-
mics analyses of tumors have demon-
strated the power of this technology to
stratify tumors into different subclasses.
However, these proof-of-principle stud-
ies did not correlate their results with the
clinical outcomes of the patients under
study (Bittner et al., 2000; Perou et al.,
2000). The study by van’t Veer et al.,
together with another study in PNAS by
Sorlie et. al., are among the first in the
breast cancer field linking expression
profiles to clinical outcome data (van’t
Veer et al., 2001; Sorlie et al., 2001).
Similarly, two groups were recently suc-
cessful in defining two subsets of diffuse
large B-cell lymphoma (DLBL) patients
having dramatically different outcomes
that could not be predicted by conven-
tional classification methods (Alizadeh et
al., 2000; Scherf et al., 2000).With these
reports on breast carcinomas and DLBL
in hand, it is already obvious that a com-
bination of clinical outcome data with
functional genomics will yield a powerful
approach for defining sets of genes
whose expression will predict outcome
and direct therapy far more effectively
than current tumor markers allow.
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